Activation of the bile acid receptor TGR5 enhances LPS-induced inflammatory responses in a human monocytic cell line

Journal of Receptors and Signal Transduction

Volumn 35, Issue 5, 2015, Pages 402-409

  Mobraten, Kaia ^a   Haugbro, Tarjei ^a   Karlstrom, Ellen ^a   Kleiveland, Charlotte R ^a,b   Lea, Tor ^a  

^a NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^b Østfold Hospital Trust   (Norway)

Author keywords

Cytokines; G protein coupled receptor; lipopolysaccharide; NFkBs and inflammation

Indexed keywords

BETULIC ACID; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG; GPBAR1 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; LIPOPOLYSACCHARIDE; TLR4 PROTEIN, MOUSE;

ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; INFLAMMATION; MONOCYTE; SIGNAL TRANSDUCTION; CELL LINE; CHEMICALLY INDUCED; IMMUNOLOGY; METABOLISM; PATHOLOGY;

CELL LINE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; LIPOPOLYSACCHARIDES; MONOCYTES; RECEPTORS, G-PROTEIN-COUPLED; TOLL-LIKE RECEPTOR 4;

EID: 84944876126     PISSN: 10799893     EISSN: 15324281     Source Type: Journal    
DOI: 10.3109/10799893.2014.986744     Document Type: Article

References (46)

1. Steiner C, Othman A, Saely CH, et al. Bile acid metabolites in serum: intraindividual variation and associations with coronary heart disease, metabolic syndrome and diabetes mellitus. PLoS One 2011; 6: e25006
2. Angelin B, Bjorkhem I, Einarsson K, Ewerth S. Hepatic uptake of bile acids in man. Fasting and postprandial concentrations of individual bile acids in portal venous and systemic blood serum. J Clin Invest 1982; 70: 724-31
3. Maruyama T, Miyamoto Y, Nakamura T, et al. Identification of membrane-type receptor for bile acids (M-BAR). Biochem Biophys Res Commun 2002; 298: 714-19
4. Keitel V, Cupisti K, Ullmer C, et al. The membrane-bound bile acid receptor TGR5 is localized in the epithelium of human gallbladders. Hepatology 2009; 50: 861-70
5. Kawamata Y, Fujii R, Hosoya M, et al. A G protein-coupled receptor responsive to bile acids. J Biol Chem 2003; 278: 9435-40
6. Watanabe M, Houten SM, Mataki C, et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006; 439: 484-9
7. Thomas C, Gioiello A, Noriega L, et al. TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab 2009; 10: 167-77
8. Keitel V, Donner M, Winandy S, et al. Expression and function of the bile acid receptor TGR5 in Kupffer cells. Biochem Biophys Res Commun 2008; 372: 78-84
9. Pols TW, Nomura M, Harach T, et al. TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab 2011; 14: 747-57
10. Ghoshal S, Witta J, Zhong J, et al. Chylomicrons promote intestinal absorption of lipopolysaccharides. J Lipid Res 2009; 50: 90-7
11. Neal MD, Leaphart C, Levy R, et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol 2006; 176: 3070-9
12. Jialal I, Huet BA, Kaur H, et al. Increased toll-like receptor activity in patients with metabolic syndrome. Diabetes Care 2012; 35: 900-4
13. Pussinen PJ, Havulinna AS, Lehto M, et al. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care 2011; 34: 392-7
14. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 2007; 56: 1986-98
15. Kim F, Pham M, Luttrell I, et al. Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res 2007; 100: 1589-96
16. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007; 56: 1761-72
17. Carlsen H, Moskaug JO, Fromm SH, Blomhoff R. In vivo imaging of NF-kappa B activity. J Immunol 2002; 168: 1441-6
18. Genet C, Strehle A, Schmidt C, et al. Structure-activity relationship study of betulinic acid, a novel and selective tgr5 agonist, and its synthetic derivatives: potential impact in diabetes. J Med Chem 2010; 53: 178-90
19. Yang JI, Yoon JH, Myung SJ, et al. Bile acid-induced TGR5-dependent c-Jun-N terminal kinase activation leads to enhanced caspase 8 activation in hepatocytes. Biochem Biophys Res Commun 2007; 361: 156-61
20. Yasuda H, Hirata S, Inoue K, et al. Involvment of membrane-type bile acid receptor M-BART/TGR5 in bile acid-induced activation of epidermal growth factor receptor and mitogen-activated protein kinases in gastric carcinoma cells. Biochem Biophys Res Commun 2006; 354: 154-9
21. Jin J, Samuvel DJ, Zhang X, et al. Coactivation of TLR4 and TLR2/6 coordinates an additive augmentation on IL-6 gene transcription via p38MAPK pathway in U937 mononuclear cells. Mol Immunol 2011; 49: 423-32
22. Wang YD, Chen WD, Yu D, et al. The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated B cells (NF-kappaB) in mice. Hepatology 2011; 54: 1421-32
23. Thomas C, Pellicciari R, Pruzanski M, et al. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008; 7: 678-93
24. Jin J, Sundararaj KP, Samuvel DJ, et al. Different signaling mechanisms regulating IL-6 expression by LPS between gingival fibroblasts and mononuclear cells: seeking the common target. Clin Immunol 2012; 143: 188-99
25. Vermeulen L, De Wilde G, Van Damme P, et al. Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 2003; 22: 1313-24
26. Saha RN, Jana M, Pahan K. MAPK p38 regulates transcriptional activity of NF-kappaB in primary human astrocytes via acetylation of p65. J Immunol 2007; 179: 7101-9
27. Vanden Berghe W, Plaisance S, Boone E, et al. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem 1998; 273: 3285-90
28. Olson CM, Hedrick MN, Izadi H, et al. p38 mitogen-activated protein kinase controls NF-kappaB transcriptional activation and tumor necrosis factor alpha production through RelA phosphorylation mediated by mitogen- and stress-activated protein kinase 1 in response to Borrelia burgdorferi antigens. Infect Immun 2007; 75: 270-7
29. Stein B, Baldwin AS Jr, Ballard DW, et al. Cross-coupling of the NF-kappa B p65 and Fos/Jun transcription factors produces potentiated biological function. EMBO J 1993; 12: 3879-91
30. You X, Wu Y, Zeng Y, et al. Mycoplasma genitalium-derived lipid-associated membrane proteins induce activation of MAPKs, NF-kappaB and AP-1 in THP-1 cells. FEMS Immunol Med Microbiol 2008; 52: 228-36
31. Kida Y, Kobayashi M, Suzuki T, et al. Interleukin-1 stimulates cytokines, prostaglandin E2 and matrix metalloproteinase-1 production via activation of MAPK/AP-1 and NF-kappaB in human gingival fibroblasts. Cytokine 2005; 29: 159-68
32. Kim JH, Song AR, Sohn HJ, et al. IL-1beta and IL-6 activate inflammatory responses of astrocytes against Naegleria fowleri infection via the modulation of MAPKs and AP-1. Parasite Immunol 2013; 35: 120-8
33. Dandona P, Ghanim H, Bandyopadhyay A, et al. Insulin suppresses endotoxin-induced oxidative, nitrosative, and inflammatory stress in humans. Diabetes Care 2010; 33: 2416-23
34. Agwunobi AO, Reid C, Maycock P, et al. Insulin resistance and substrate utilization in human endotoxemia. J Clin Endocrinol Metab 2000; 85: 3770-8
35. Mehta NN, McGillicuddy FC, Anderson PD, et al. Experimental endotoxemia induces adipose inflammation and insulin resistance in humans. Diabetes 2009; 59: 172-81
36. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell 2012; 148: 852-71
37. Nakatani Y, Kaneto H, Kawamori D, et al. Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 2004; 279: 45803-9
38. Kaneto H, Nakatani Y, Miyatsuka T, et al. Possible novel therapy for diabetes with cell-permeable JNK-inhibitory peptide. Nat Med 2004; 10: 1128-32
39. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-6
40. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001; 108: 437-46
41. Gao Z, Hwang D, Bataille F, et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J Biol Chem 2002; 277: 48115-21
42. Yuan M, Konstantopoulos N, Lee J, et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 2001; 293: 1673-7
43. Jager J, Gremeaux T, Cormont M, et al. Interleukin-1beta-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression. Endocrinology 2007; 148: 241-51
44. Aguirre V, Uchida T, Yenush L, et al. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). J Biol Chem 2000; 275: 9047-54
45. de Alvaro C, Teruel T, Hernandez R, Lorenzo M. Tumor necrosis factor alpha produces insulin resistance in skeletal muscle by activation of inhibitor kappaB kinase in a p38 MAPK-dependent manner. J Biol Chem 2004; 279: 17070-8
46. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-90